BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GE Capital Closes $7.5 Million Term Loan Facility for Trimel Pharmaceuticals Corporation


8/9/2012 8:22:11 AM

BETHESDA, Md.--(BUSINESS WIRE)-- GE Capital, Healthcare Financial Services announced today that it was sole lender and administrative agent on a $7.5 million senior secured term loan facility for Trimel Pharmaceuticals Corporation (TRL.TO). The financing will be used for working capital to support ongoing clinical development.

Based in Ontario, Canada, Trimel Pharmaceuticals Corporation is a unique specialty pharmaceutical company actively developing medications for men’s health, female sexual health and various respiratory disorders. The company holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and owns a novel dry powder drug delivery technology platform. They are actively pursuing the development and application of these technologies to products that are currently in Phase II and Phase III clinical testing.

“The financing provided by GE Capital is important to our organization because it supports our ability to develop and test innovative new products,” said Kenneth Howling, CFO for Trimel Pharmaceuticals Corporation. “GE Capital understands the unique dynamics of our industry and worked closely with us to structure a financing solution to meet our needs.”

“Life science companies value having a lender dedicated to their industry who knows the unique dynamics impacting their success,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. “With our industry knowledge and strong balance sheet, we deliver flexible and reliable loans to customers.”

About GE Capital, Healthcare Financial Services

With in-depth industry knowledge and expertise, GE Capital, Healthcare Financial Services has provided more than $60 billion in financing over ten years to companies in over 45 healthcare sectors including senior housing, hospitals, medical offices, outpatient services, pharmaceuticals and medical devices. Our team of professionals creates business and financial solutions tailored to meet the individual needs of our customers. For more information, visit gecapital.com/healthcare.

GE Capital offers consumers and businesses around the globe an array of financial products and services. For more information, visit www.gecapital.com or follow company news via Twitter (@GECapital). GE (GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. For more information, visit the company's website at www.ge.com.

Contact:

GE Capital, Americas

Ned Reynolds, 203-229-5717

ned.reynolds@ge.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES